Autumn Wilgers
Family · McPherson, KSNPI 1447558366
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 441 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 45 manufacturers, the largest accounting for just 18.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,723 and has fallen 59.1% since, to $704 in 2025. Among family clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 441 payments — averaging $14.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$758
- AstraZeneca$612
- Pfizer$610
- Amgen$609
- Novo Nordisk$397
- plus $2K from 39 others
What the payments were for
- Food & beverage$6,34298%
- Education$1142%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,456 in reported general payments places this provider in the 95th percentile of 1,579 family providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 52 | $49,290 |
| OzempicSemaglutide | 47 | $40,819 |
| EliquisApixaban | 49 | $32,306 |
| MounjaroTirzepatide | 17 | $17,596 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $16,187 |
| LinzessLinaclotide | 19 | $14,139 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $13,154 |
| MyrbetriqMirabegron | 17 | $10,322 |
| FarxigaDapagliflozin Propanediol | 11 | $10,230 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,676 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $7,500 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $6,537 |
| Ezetimibe | 50 | $3,002 |
| Omeprazole | 202 | $1,787 |
| Atorvastatin Calcium | 296 | $1,601 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $62 | $49,29052 claims |
| Novo NordiskOzempic | $397 | $40,81947 claims |
| PfizerEliquis | $610 | $32,30649 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $199 | $19,69134 claims |
| Lilly USA, LLCMounjaro | $758 | $17,59617 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $80 | $16,18717 claims |
| AbbVieLinzess, Synthroid | $1,203 | $15,00731 claims |
| Astellas Pharma US IncMyrbetriq | $127 | $10,32217 claims |
| AstraZenecaFarxiga | $612 | $10,23011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,579 family providers in Kansas.
Other family in McPherson
- Zohra HussainiKansas City$329K
- Jennifer ChesterOverland Park$327K
- Amanda CaldwellLeawood$203K
- Kayla del RioWichita$147K
- Kelli RiceWichita$114K
- Tatum TolandTopeka$108K
- Mary GonzalesWichita$87K
- Erin FeitzOverland Park$36K
- Adam CaseKansas City$34K
- Jaimie HeldstabWestwood$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.